#United States #Cambridge #Decoy Therapeutics #D-MAVs #IMP³ACT

Decoy Therapeutics to Present at Key Conferences

Decoy Therapeutics Inc., a biotechnology firm at the forefront of developing Designable Multi-Antivirals (D-MAVs™), is set to participate in two significant peptide therapeutics conferences in Boston, scheduled for the last week of April 2026. As the company pushes the boundaries of antiviral treatment, its executive team will highlight their pioneering work at these events.

Key Presentations

On April 30, Peter Marschel, Chief Business Officer of Decoy Therapeutics, will lead a roundtable discussion at the Oligonucleotide Peptides HubXchange. The session, titled "Key challenges in computational design of peptide therapeutics: From natural ligand reengineering to de novo design," will delve into the challenges and opportunities presented by generative design methods. Marschel aims to articulate how these innovative approaches can enhance peptide discovery by advancing beyond traditional evolutionary sampling methods. The ongoing collaboration with Quantori, which utilizes a Google Cloud-native and AI-driven peptide design and molecular simulation platform, is expected to significantly reduce the time from peptide conception to D-MAV candidates.

Marschel expressed enthusiasm about the potential impact of their research, stating, "The most interesting work in peptide therapeutics right now is how quickly we can move from optimizing naturally occurring ligands to designing novel ligands. At Decoy, we’re particularly focused on harnessing powerful, cross-reactive natural ligands combined with cutting-edge computational techniques to develop drug candidates that traditional approaches have struggled to yield. We look forward to sharing our insights during the conference."

The very next day, on April 28, Chief Scientific Officer Dr. Barbara Hibner and Chief Technology Officer Dr. Michael Lipp will co-present a Spotlight Case Study at the 3rd Annual Peptide-Based Therapeutics Summit. Their focus will be on the "Design and Development of Peptide Conjugate Antiviral Therapeutics." This presentation will showcase how peptide conjugates are revolutionizing the development of therapeutics tailored to specific medical needs, moving beyond the outdated one-therapeutic-for-one-virus strategy.

Innovation in Antiviral Development

Dr. Hibner pointedly noted, "For decades, antiviral treatments focused on targeting individual viruses, but with peptide conjugates, we are able to design therapeutics that target shared viral mechanisms. This shift is not just reactive; it’s a proactive approach in combating numerous viral adversaries, significantly increasing our toolkit against global health threats."

In addition, Dr. Bradley Pentelute, a distinguished Decoy Technology Advisor and MIT Professor, will inaugurate the conference on April 29 with a keynote address titled, "The Infinite Loop: Machine Learning for Discovery, Delivery and Rapid Manufacturing of Potential Medicines." His insights are expected to inspire attendees on the future possibilities of integrating machine learning into pharmaceutical development workflows.

Advancing the D-MAV Pipeline

These presentations are particularly timely as Decoy Therapeutics continues to make strides with its D-MAV pipeline, which currently emphasizes a preclinical candidate targeting pan-coronavirus strains and another in development addressing the concurrent challenges posed by influenza, COVID-19, and RSV—what has been termed the "tripledemic." This innovative work leverages the IMP3ACT platform that seamlessly integrates AI-driven peptide design with rapid synthesis methodologies.

Decoy Therapeutics, explicitly focusing on respiratory viruses, operates within a climate of increased urgency for innovative antiviral strategies. With substantial backing from various funding sources, including the Massachusetts Life Sciences Seed Fund and the Google AI startup program, the company remains committed to redefining how antiviral therapeutics are conceptualized and developed.

As the landscape of viral therapies evolves, Decoy’s approach promises not only expansive potential in addressing pressing health concerns but also a transformative impact on therapeutic design that could lead to more adaptable and effective solutions for future viral outbreaks.